Thombs Brett D, de Jonge Peter, Coyne James C, Whooley Mary A, Frasure-Smith Nancy, Mitchell Alex J, Zuidersma Marij, Eze-Nliam Chete, Lima Bruno B, Smith Cheri G, Soderlund Karl, Ziegelstein Roy C
Department of Psychiatry, McGill University, Montréal, Québec, Canada.
JAMA. 2008 Nov 12;300(18):2161-71. doi: 10.1001/jama.2008.667.
Several practice guidelines recommend that depression be evaluated and treated in patients with cardiovascular disease, but the potential benefits of this are unclear.
To evaluate the potential benefits of depression screening in patients with cardiovascular disease by assessing (1) the accuracy of depression screening instruments; (2) the effect of depression treatment on depression and cardiac outcomes; and (3) the effect of screening on depression and cardiac outcomes in patients in cardiovascular care settings.
MEDLINE, PsycINFO, CINAHL, EMBASE, ISI, SCOPUS, and Cochrane databases from inception to May 1, 2008; manual journal searches; reference list reviews; and citation tracking of included articles.
We included articles in any language about patients in cardiovascular care settings that (1) compared a screening instrument to a valid major depressive disorder criterion standard; (2) compared depression treatment with placebo or usual care in a randomized controlled trial; or (3) assessed the effect of screening on depression identification and treatment rates, depression, or cardiac outcomes.
Methodological characteristics and outcomes were extracted by 2 investigators.
We identified 11 studies about screening accuracy, 6 depression treatment trials, but no studies that evaluated the effects of screening on depression or cardiovascular outcomes. In studies that tested depression screening instruments using a priori-defined cutoff scores, sensitivity ranged from 39% to 100% (median, 84%) and specificity ranged from 58% to 94% (median, 79%). Depression treatment with medication or cognitive behavioral therapy resulted in modest reductions in depressive symptoms (effect size, 0.20-0.38; r(2), 1%-4%). There was no evidence that depression treatment improved cardiac outcomes. Among patients with depression and history of myocardial infarction in the ENRICHD trial, there was no difference in event-free survival between participants treated with cognitive behavioral therapy supplemented by an antidepressant vs usual care (75.5% vs 74.7%, respectively).
Depression treatment with medication or cognitive behavioral therapy in patients with cardiovascular disease is associated with modest improvement in depressive symptoms but no improvement in cardiac outcomes. No clinical trials have assessed whether screening for depression improves depressive symptoms or cardiac outcomes in patients with cardiovascular disease.
多项实践指南建议对心血管疾病患者进行抑郁症评估和治疗,但其潜在益处尚不清楚。
通过评估(1)抑郁症筛查工具的准确性;(2)抑郁症治疗对抑郁症及心脏结局的影响;(3)筛查对心血管护理环境中患者的抑郁症及心脏结局的影响,来评估心血管疾病患者抑郁症筛查的潜在益处。
从创刊至2008年5月1日的MEDLINE、PsycINFO、CINAHL、EMBASE、ISI、SCOPUS和Cochrane数据库;手工期刊检索;参考文献列表回顾;以及对纳入文章的引文追踪。
我们纳入了任何语言的关于心血管护理环境中患者的文章,这些文章(1)将一种筛查工具与有效的重度抑郁症标准进行比较;(2)在一项随机对照试验中将抑郁症治疗与安慰剂或常规护理进行比较;或(3)评估筛查对抑郁症识别率、治疗率、抑郁症或心脏结局的影响。
由两名研究人员提取方法学特征和结局。
我们确定了11项关于筛查准确性的研究、6项抑郁症治疗试验,但没有评估筛查对抑郁症或心血管结局影响的研究。在使用预先定义的临界值分数测试抑郁症筛查工具的研究中,敏感性范围为39%至100%(中位数为84%),特异性范围为58%至94%(中位数为79%)。药物治疗或认知行为疗法治疗抑郁症可使抑郁症状适度减轻(效应量为0.20 - 0.38;r²为1% - 4%)。没有证据表明抑郁症治疗能改善心脏结局。在ENRICHD试验中,有心肌梗死病史的抑郁症患者中,接受认知行为疗法加抗抑郁药治疗的参与者与接受常规护理的参与者之间的无事件生存率没有差异(分别为75.5%和74.7%)。
心血管疾病患者使用药物或认知行为疗法治疗抑郁症与抑郁症状适度改善相关,但对心脏结局无改善。尚无临床试验评估抑郁症筛查是否能改善心血管疾病患者的抑郁症状或心脏结局。